Legal challenges of US Food and Drug Administration exclusivity determinations are among the early cases where the Supreme Court’s overturning of the Chevron doctrine of deference is being cited.
The 28 June decision in Loper Bright v. Raimondo and Relentless v
Key Takeaways
-
Parties involved in litigation with the FDA over drugs and biologics are starting to cite the Supreme Court’s Loper Bright decision in court filings.
-
Early cases that reference the elimination of Chevron deference include several involving marketing exclusivity determinations